非小细胞肺癌靶向治疗药物的研究  

Research progress in targeted therapy of non small cell lung cancer

作　　者：邱燕军[1] 吕定量[1] 郭劝民[1] QIU Yan-jun LV Ding-liang GUO Quan-min(Department of Cardiothoracic Surgery, Quzhou People＇s Hospital, Quzhou 324000, Chin)

机构地区：[1]浙江省衢州市人民医院心胸外科

出　　处：《中国生化药物杂志》2017年第6期441-442,448,共3页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的 探讨靶向药物治疗非小细胞肺癌临床应用效果.方法 研究组给予吉非替尼靶向药物治疗,对照组给予厄洛替尼靶向药物治疗,记录2组非小细胞肺癌患者近期疗效、随访生存时间、治疗费用、不良反应（药物相关）发生情况.结果 研究组近期治疗总有效率（37.50%）与对照组（近期治疗总有效率35.42%）对比差异无统计学意义;2组非小细胞肺癌患者中位生存时间对比并差异无统计学意义,但研究组治疗费用显著少于对照组（P〈0.05）;2组非小细胞肺癌患者分别经厄洛替尼、吉非替尼靶向治疗过程中不良反应发生情况对比并差异无统计学意义.结论 经吉非替尼靶向治疗非小细胞肺癌可在保障临床疗效及预后的基础上,有效减轻患者治疗经济压力,更有利于其积极接受并配合治疗.Objective To investigate the clinical effect of targeted drug therapy for non-small cell lung cancer.MethodsThe study group received gefitinib targeted drug therapy, the control group was given erlotinib treatment, recording two groups of patients with non-small cell lung cancer, survival time, follow-up treatment costs and adverse reaction incidence （drug）.ResultsThe total efficiency of treatment （37.50%） and the control group （the total efficiency of treatment 35.42%） no obvious difference;no significant difference between the survival time of patients in group two non-small cell lung cancer, but the study group treatment costs significantly less than the control group （P〈0.05）;two groups of patients with non-small cell lung cancer were treated with erlotinib and gefitinib poisoning reaction contrast did not significant difference.ConclusionGefinitib targeted therapy of non-small cell lung cancer can be based on protecting the clinical curative effect and prognosis of the patients, reduce the economic pressure, more conducive to the positive reception and treatment.

关 键 词：非小细胞肺癌 靶向药物 治疗效果 

分 类 号：R734.2[医药卫生—肿瘤]